Nerandomilast (BI 1015550) is an orally administered preferential inhibitor of phosphodiesterase 4B. In preclinical models of lung fibrosis, nerandomilast showed antifibrotic and immunomodulatory ...

In this randomized trial, among patients with idiopathic pulmonary fibrosis (IPF), nerandomilast slowed the decline in the ...

SAN FRANCISCO — Reduced doses in antifibrotic therapy for patients with idiopathic pulmonary fibrosis did not significantly impact outcomes, according to an abstract presented at the American ...

In patients not taking background antifibrotic therapy, the FVC decline was –79.2 mL for the 18-mg nerandomilast group compared with –148.7 mL for placebo.

Drs Jeffrey Swigris and Ayodeji Adegunsoye discuss fibrosing interstitial lung disease and treatment challenges for individuals with idiopathic pulmonary fibrosis.

References: Bristol Myers Squibb announces US FDA Breakthrough Therapy designation for investigational LPA 1 antagonist for progressive pulmonary fibrosis. News release. October 24, 2023. https ...

Akero Therapeutics Reveals AI-Based Analysis Supporting Efruxifermin's Antifibrotic Activity in Phase 2b HARMONY Trial for Pre-Cirrhotic MASH ...

Cardillo C, Criner GJ, Gayen S. Antifibrotic therapy combined with pulmonary vasodilator therapy may improve survival in patients with pulmonary fibrosis and pulmonary hypertension: ...

The Antifibrotic Effect of Interferon Alfa in the Treatment of Chronic Hepatitis C: An Unanticipated but Important End Point. MedGenMed 2(3), 2000 [formerly published in Medscape Gastroenterology ...

Novel Antifibrotic Improved Fibrosis in Chronic Hepatitis B — Phase II trial from China suggests benefit of add-on therapy by Zaina Hamza , Staff Writer, MedPage Today July 15, 2022 ...

HONOLULU -- A reduced-dose regimen of the antifibrotic medication nintedanib (Ofev) held up in real-world clinical practice, an observational study found.

As the only industry-led forum providing biopharma with the insights necessary to make strategic and scientific decisions on their fibrosis pipeline, the 6th Antifibrotic Drug Development Summit ...